Is Hormone Therapy Safe? Why the FDA Dropped Its Scariest Warnings

If you were told hormone therapy causes breast cancer and heart attacks, you're not alone. That message came from one study in 2002, and it kept a generation of women away from the most effective menopause treatment there is.

Then, in November 2025, the FDA moved to pull its scariest warnings off hormone therapy labels. So what changed? Here's the story, who's a good candidate, and the real risks in plain numbers.

The 2002 study that scared everyone

The Women's Health Initiative (WHI) was a huge trial. More than 16,000 women took either a daily estrogen-plus-progestin pill or a placebo. In 2002, it was stopped early because breast cancer cases in the hormone group crossed a safety line.

The headlines were terrifying. Many women stopped their hormones, and many doctors stopped offering them.

But headlines reported relative risk. Here's what the study actually found per 10,000 women each year on hormones, compared with placebo:

• 8 more breast cancers, 7 more heart events, 8 more strokes, and 8 more lung clots.
• 6 fewer colorectal cancers and 5 fewer hip fractures.

Those are real risks. They're also much smaller than "hormones cause cancer" suggests.

What the follow-up showed

Researchers kept following these women for two more decades. The picture got a lot more nuanced.

• The women were older than most new users. The average age was 63. Symptoms usually hit in the late 40s or early 50s, and the average age of menopause is 51.
• Deaths didn't go up. After 18 years of follow-up, 27.1% of women who took hormones had died, compared with 27.6% on placebo. That's no meaningful difference.
• Estrogen alone looked different. In women who'd had a hysterectomy and took estrogen without a progestin, breast cancer was less common than on placebo, and so were breast cancer deaths.
• Age changed the math. Younger women in their 50s had more favorable results than women in their 70s.

What the FDA changed in 2025

On November 10, 2025, the FDA announced it was starting to remove boxed warnings from menopausal hormone therapy. A boxed warning is the strongest warning a drug label can carry. Here's what changed:

• Removed from the boxed warning: heart disease, breast cancer, and probable dementia. That information still appears elsewhere on the label.
• Kept: the boxed warning about endometrial (uterine) cancer for systemic estrogen-alone products, since estrogen without a progestin can thicken the uterine lining.
• Dropped: the old advice to use "the lowest effective dose for the shortest duration."
• Added: guidance to consider starting systemic hormones for hot flashes before age 60 or within 10 years of menopause.

The FDA approved the first relabeled products in February 2026, covering every type of menopausal hormone product, including vaginal estrogen, and more have followed. Not every expert agrees with every change, and many stress that a careful one-on-one conversation matters more than ever. But the direction is clear: age and timing are now front and center.

Timing is everything

The single most important factor is when you start. The Menopause Society's 2022 position statement puts it simply:

• Under 60, or within 10 years of menopause, with no reason to avoid it: the benefits outweigh the risks for bothersome hot flashes and for preventing bone loss.
• Over 60, or more than 10 years out: the balance is less favorable, because the absolute risks of heart disease, stroke, blood clots, and dementia are higher.

One leading explanation: estrogen seems to act differently on healthy blood vessels than on vessels with years of plaque already built up. Think of it like a coat of paint. It protects fresh wood, but it can't fix wood that's already rotting.

There's also no automatic stop date. Women with ongoing symptoms can keep going, with regular check-ins to make sure it still makes sense.

Who's a good candidate

Not sure your symptoms are menopause? Start with the signs nobody warned you about. You might be a strong candidate for hormones if you:

• Have hot flashes or night sweats that disrupt your sleep, work, or mood.
• Are under 60 or within about 10 years of your last period.
• Went through menopause early or have reasons to protect your bones.
• Have vaginal dryness or painful sex, which can respond to low-dose vaginal estrogen even when systemic hormones aren't right.

Systemic hormone therapy usually isn't recommended if you've had breast or endometrial cancer, a stroke, a heart attack, blood clots, or liver disease, or if you're pregnant. Unexplained vaginal bleeding needs to be checked first.

The real risks, in plain words

No medicine is risk-free. Here's what to know:

• Blood clots and stroke. The risk is small and rises with age. Pills carry more risk than estrogen through the skin, like patches, gels, and sprays.
• Breast cancer. Estrogen plus a progestin raises the risk slightly, especially with longer use. Estrogen alone didn't raise it in the WHI.
• Uterine cancer. If you have a uterus, estrogen needs a progestogen to protect the lining. That's why most women take both.
• Gallbladder disease. A small increase, highest with pills.
• Everyday side effects. Breast soreness, bloating, headaches, and spotting can happen early on. Spotting usually stops within 6 months, and a dose change often helps the rest.

How Nirvanix approaches hormone therapy

Your Nirvanix clinician starts with your symptoms, your age, how long it's been since your last period, and your personal and family history. Then you talk through routes, doses, and alternatives, including nonhormonal options. You check in as you go, and your plan changes if it needs to. It all happens online, and the consultation is included.

The bottom line

The 2002 scare was based on older women taking one specific pill, and two decades of follow-up softened the picture a lot. For most healthy women under 60 or within 10 years of menopause, hormone therapy's benefits outweigh its risks, and the FDA's label now reflects that.

Wondering if it's right for you? Take the two-minute quiz to see where to start.